U.S. stocks mixed ahead of Fed decision
Investing.com - The U.S. Department of Health and Human Services (HHS) and Food and Drug Administration (FDA) announced reforms on September 9, 2025, targeting what they describe as misleading direct-to-consumer (DTC) pharmaceutical advertising. These reforms could significantly impact major players like Pfizer (NYSE: PFE), which InvestingPro data shows is a prominent player in the Pharmaceuticals industry with $63.8 billion in revenue over the last twelve months.
The regulatory actions include issuing thousands of warning letters, approximately 100 cease-and-desist notices, and initiating rulemaking to close the "adequate provision loophole" in pharmaceutical advertising regulations.
A presidential memorandum from President Donald J. Trump accompanied the announcement, granting HHS leadership authority to enforce greater transparency and fair balance requirements in drug advertisements.
Raymond James analysts note that pharmaceutical companies may face significant compliance challenges, increased advertising costs, and may need to adopt more conservative advertising approaches as a result of these reforms.
The investment firm also highlights that pharmaceutical companies might hesitate to challenge these reforms legally, as doing so could risk making them targets for other Trump administration actions, including Medicare drug price negotiations. According to InvestingPro analysis, Pfizer currently appears undervalued, suggesting potential resilience despite regulatory challenges. InvestingPro subscribers can access over 10 additional exclusive insights about Pfizer’s financial health and market position.
In other recent news, Pfizer Inc has reaffirmed its commitment to transparent disclosure of research findings related to its COVID-19 vaccine, emphasizing the integrity of ongoing studies. This announcement comes amid reports that the Trump administration may consider banning COVID-19 vaccines, a move allegedly supported by influential figures. Additionally, Pfizer has entered a new clinical trial collaboration with Olema Pharmaceuticals to evaluate a combination therapy for metastatic breast cancer, focusing on the safety and combinability of their respective drugs. Meanwhile, the U.S. Food and Drug Administration has approved updated COVID-19 vaccines with more restricted eligibility, primarily for those over 65 or with underlying health conditions.
In terms of analyst ratings, Cantor Fitzgerald has maintained a Neutral rating on Pfizer with a price target of $24. The firm highlighted Pfizer’s ability to deliver earnings per share and outperform growth-challenged peers. This analysis comes in the context of Pfizer’s ongoing efforts to navigate challenges in the pharmaceutical sector. These developments reflect Pfizer’s strategic initiatives and the broader landscape of the healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.